Reactions of functionalized sulfonamides: Application to lowering the lipophilicity of cytosolic phospholipase A 2α inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 4, 2009, Pages 1156-1171

  Chen, Lihren ^a   Wang, Weiheng ^a   Lee, Katherine L ^a   Shen, Marina W H ^a   Murphy, Elizabeth A ^a   Zhang, Wen ^a   Xu, Xin ^a   Tam, Steve ^a   Nickerson Nutter, Cheryl ^a   Goodwin, Debra G ^a   Clark, James D ^a   McKew, John C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 FORMYLPHENYL)METHANESULFONYL CHLORIDE; 2 FORMYLPHENYLMETHANE SULFONAMIDE; ALIPHATIC AMINE; AROMATIC COMPOUND; METHYL 4 [2 [1 BENZHYDRYL 5 CHLORO 2 [2 (((CHLOROMETHYL)SULFONYL)AMINO)ETHYL] 1H INDOL 3 YL]ETHOXY]BENZOATE; METHYL 4 [2 [5 CHLORO 1 (DIPHENYLMETHYL) 2 (2 ((VINYLSULFONYL)AMINO)ETHYL) 1H INDOL 3 YL]ETHOXY]BENZOATE; METHYL 4 [3 [5 CHLORO 1 (DIPHENYLMETHYL) 2 (2 (((2 FORMYLBENZYL)SULFONYL)AMINO)ETHYL) 1H INDOL 3 YL]PROPYL]BENZOATE; METHYL 4 [3 [5 CHLORO 1 (DIPHENYLMETHYL) 2 (2 ((VINYLSULFONYL)AMINO)ETHYL) 1H INDOL 3 YL]PROPYL]BENZOATE; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPASE A2ALPHA INHIBITOR; SULFONAMIDE; UNCLASSIFIED DRUG;

AMINATION; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; LIPOPHILICITY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ENZYME INHIBITORS; GROUP IV PHOSPHOLIPASES A2; HYDROPHOBICITY; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES; SULFONAMIDES;

EID: 64349091726     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8009876     Document Type: Article

References (34)

1. 2. J. Lipid Mediators Cell Signaliing 1995, 12, 83-117.
2. 2 enzymes on product-containing vesicles: application to the determination of substrate preferences. Biochemistry 1993, 32, 5949-5958.
3. 2. Anti-Inflammatory Anti-Allergy Agents Med. Chem. 2006, 5 (2), 189-203.
4. 2 by novel 2-oxoamides in vitro, in cells, and in vivo. J. Med. Chem. 2004, 47(14), 3615-3628.
5. 2 in allergic response and parturition. Nature 1997, 390 (6660), 618-622.
6. 2a-deficient mice are resistant to collagen-induced arthritis. J. Exp. Med. 2003, 197 (10), 1297-1302.
7. 2 Are Less Susceptible to Cerebral Ischemia/Reperfusion Injury Brain Edema XII, Proceedings of the 12th International Symposium, Hakone, Japan, Nov 10-13, 2002; Springer: Berlin, 2003; pp 169-172.
8. 2α-deficient mice are resistant to experimental autoimmune encephalomyelitis. J. Exp. Med. 2005, 202 (6), 841-851.
9. (e) Bonventre, J. V.; Huang, Z.; Taheri, M. R.; O'Leary, E.; Li, E.; Moskowitz, M. A.; Sapirstein, A. Reduced fertility and postischemic brain injury in mice deficient in cytosolic phospholipase A2. Nature (London) 1997, 390 (6660), 622-625.
10. (f) Hong, K. H.; Bonventre, J. C.; O'Leary, E.; Bonventre, J. V.; Lander, E. S. Deletion of cytosolic phospholipase A2 suppresses ApcMin-induced tumori- genesis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (7), 3935-3939.
11. (a) McKew, J. C.; Lee, K. L.; Shen, M. W. H.; Thakker, P.; Foley, M. A.; Behnke, M. L.; Hu, B.; Sum, F.-W.; Tam, S.; Hu, Y.; Chen, L.; Kirincich, S. J.; Michalak, R.; Thomason, J.; Ipek, M.; Wu, K.; Wooder, L.; Ramarao, M. K.; Murphy, E. A.; Goodwin, D. G.; Albert, L.; Xu, X.; Donahue, F.; Ku, M. S.; Keith, J.; Nickerson- Nutter, C. L.; Abraham, W. M.; William, C.; Hegen, M.; Clark, J. D. Discovery and in vitro and in vivo characterization of 4-{3- [5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphe- nylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib. J. Med. Chem. 2008, 51, 3388-3413.
12. 2α: optimization of in vitro potency and rat pharma- cokinetics for oral efficacy. Bioorg.Med.Chem. 2008,16, 1345-1358.
13. 2α. J. Med. Chem. 2007, 50, 1380-1400.
14. 2α: hit to lead optimization. J. Med. Chem. 2006, 49 (1), 135-158.
15. (e) McKew, J. C.; Lovering, F.; Clark, J. D.; Bemis, J.; Xiang, Y.; Shen, M.; Zhang, W.; Alvarez, J. C.; Joseph- McCarthy, D. Structure-activity relationships of indole cytosolic phospholipase A2a inhibitors: substrate mimetics. Bioorg. Med. Chem. Lett. 2003, 13 (24), 4501-4504.
16. Ono, T.; Yamada, K.; Chikazawa, Y.; Ueno, M.; Nakamoto, S.; Okuno, T.; Seno, K. Characterization of a novel inhibitor of cytosolic phospholipase A2a, pyrrophenone. Biochem. J. 2002, 363 (3), 727-735.
17. Dessen, A.; Tang, J.; Schmidt, H.; Stahl, M.; Clark, J. D.; Seehra, J.; Somers, W. S. Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. Cell 1999, 97, 349-360.
18. (a) Lipinski, C. A. Integration of physicochemical property considerations into the design of combinatorial libraries. Pharm. News 2002, 9, 195-202.
19. (b) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
20. Michalak, R. S.; Helom, J. L.; Zeldis, J. Process for the Synthesis of Sulfonyl Halides and Sulfonamides from Sulfonic Acid Salts. U.S. Pat. Appl. Publ. US 2007021614 A1 20070125, 2007; 13 pp.
21. (a) Hromatka, O.; Knollmueller, M.; Binder, D. Syntheses of 1,3- dihydro-2,1,4-benzothiadiazepines. Monatsh. Chem. 1969, 700, 872-878.
22. (b) Griffiths, D.; Hull, R.; Seden, T. P. The chemistry of o-phenylenediisothiocyanate. Part 3. Studies on the syntheses of heterocyclic compounds. J. Chem. Soc., Perkin Trans 1 1980, (11), 2608-2611.
23. (a) Frankel, M.; Moses, P. Syntheses of amino alkyl sulphonic acids and their peptide analogues. Tetrahedron 1960, 9, 289-294.
24. (b) Moe, G. R.; Sayre, L. M.; Portoghese, P. S. An explanation for the failure of aminomethanesulfonic acid to form sulfonamides. Acyl chloride- promoted generation of a-carboxamidoalkylating electrophiles. Tetrahedron Lett. 1981, 22, 537-540.
25. Ashford, S. W.; Grega, K. C. Oxidative cleavage of 1,3-dicarbonyls to carboxylic acids with oxone. J. Org. Chem. 2001, 66, 1523-1524.
26. (a) Wolfe, J. P.; Tomori, H.; Sadighi, J. P.; Yin, J.; Buchwald, S. L. Simple, efficient catalyst system for the palladium-catalyzed amination of aryl chlorides, bromides, and triflates. J. Org. Chem. 2000, 65, 1158-1174.
27. (b) Hartwig, J. F. Transition metal catalyzed synthesis of arylamines and aryl ethers from aryl halides and triflates: scope and mechanism. Angew. Chem., Int. Ed. 1998, 37, 2046-2067.
28. King, J. F.; Hawson, A.; Huston, B. L.; Danks, L. J.; Komery, J. Chlorination of heterocyclic and acyclic sulfonhydrazones. Can. J. Chem. 1971, 49, 943-955.
29. (a) Abraham, W. M.; Ahmed, A.; Cortes, A.; Sielczak, M. W.; Hinz, W.; Bouska, J.; Lanni, C.; Bell, R. L. The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep. Eur. J. Pharmacol. 1992, 217 (2-3), 119-126.
30. (b) Bell, R. L. The development of zileuton (ZYFLO) and the N-hydroxyurea class of 5-lipoxygenase inhibitors. Novel Inhibitors Leukotrienes 1999, 235-249.
31. Smith, C. J.; Zhang, Y.; Koboldt, C. M.; Muhammad, J.; Zweifel,B. S.; Shaffer, A.; Talley, J. J.; Masferrer, J. L.; Seibert, K.; Isakson, P. C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. U.S.A. 1998, 95 (22), 13313-13318.
32. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]benzenesulfonamide (SC-58635, celecoxib). J. Med. Chem. 1997, 40 (9), 1347-1365.
33. (a) Mukherjee, A.; Hale, V. G.; Borga, O.; Stein, R. Predictability of the clinical potency of NSAIDs from the preclinical pharma- codynamics in rats. Inflammation Res. 1996, 45 (11), 531-540.
34. (b) Otterness, I. G.; Bliven, M. L. Laboratory Models for Testing Nonsteroidal Antiinflammatory Drugs; John Wiley & Sons: New York, 1985; pp 111-251.